UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-36582
Altamira Therapeutics Ltd.
(Exact name of registrant as specified in its charter)
Clarendon
House
2
Church Street
Hamilton HM11
Bermuda
+1
(441) 295 59 50
(Address,
including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common
shares, par value $0.002 per share
(Title
of each class of securities covered by this Form)
None
(Titles
of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please
place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file
reports:
| |
Rule 12g-4(a)(1) |
☒ |
|
| |
Rule 12g-4(a)(2) |
☐ |
|
| |
Rule 12h-3(b)(1)(i) |
☒ |
|
| |
Rule 12h-3(b)(1)(ii) |
☐ |
|
| |
Rule 15d-6 |
☐ |
|
| |
Rule 15d-22(b) |
☐ |
|
Approximate
number of holders of record of the common stock: 48
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, Altamira Therapeutics Ltd. has caused this certification/notice
to be signed on its behalf by the undersigned duly authorized person.
| |
|
| |
|
| Date:
February 27, 2026 |
By: |
/s/
Thomas Meyer |
| |
Name: |
Thomas
Meyer |
| |
Title: |
Chief
Executive Officer |
